Roger J. Hajjar

Active 1988–2025

192
Papers
33,678
Citations
110
h-index
189
i10-index

Citations

Citations per year for Roger J. Hajjar1986: 1 citations1988: 1 citations1990: 2 citations1991: 6 citations1992: 9 citations1993: 3 citations1994: 10 citations1995: 15 citations1996: 13 citations1997: 30 citations1998: 62 citations1999: 71 citations2000: 138 citations2001: 118 citations2002: 177 citations2003: 197 citations2004: 233 citations2005: 165 citations2006: 170 citations2007: 212 citations2008: 233 citations2009: 221 citations2010: 216 citations2011: 223 citations2012: 336 citations2013: 319 citations2014: 373 citations2015: 332 citations2016: 277 citations2017: 331 citations2018: 356 citations2019: 1,083 citations2020: 1,181 citations2021: 1,330 citations2022: 972 citations2023: 755 citations2024: 1,083 citations2025: 546 citations2026: 8 citations1987: no citations, so this year is not shown1989: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,910 citing papers, 29.7% of this breakdownChina: 1,943 citing papers, 14.7% of this breakdownGermany: 868 citing papers, 6.6% of this breakdownUnited Kingdom: 754 citing papers, 5.7% of this breakdownItaly: 540 citing papers, 4.1% of this breakdownCanada: 482 citing papers, 3.6% of this breakdownNetherlands: 421 citing papers, 3.2% of this breakdownJapan: 360 citing papers, 2.7% of this breakdownFrance: 324 citing papers, 2.5% of this breakdownAustralia: 278 citing papers, 2.1% of this breakdownSpain: 275 citing papers, 2.1% of this breakdownIndia: 180 citing papers, 1.4% of this breakdown
0%29.7%Other 21.6%

Fields

  • Medicine47%
  • Biochemistry, Genetics and Molecular Biology43.7%
  • Neuroscience2.5%
  • Engineering2%
  • Immunology and Microbiology1.7%
  • Computer Science0.6%
  • Other2.5%

Topics

  • Cardiac electrophysiology and arrhythmias3.5%
  • Cardiac Fibrosis and Remodeling3.4%
  • Cardiovascular Function and Risk Factors3%
  • Cardiomyopathy and Myosin Studies2.7%
  • Tissue Engineering and Regenerative Medicine2.5%
  • Congenital heart defects research2.4%
  • Other82.5%

Coauthors

All papers

Open in search
  1. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

    Authors: , , , , , , , , , , , - Journal of the American College of Cardiology 2019 cited by 662

  2. FTO-Dependent N 6 -Methyladenosine Regulates Cardiac Function During Remodeling and Repair

    Authors: , , , , , , , , , , , , , , , , , , - Circulation 2018 cited by 597

  3. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2016 cited by 613

  4. Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration

    Authors: , , , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 285

  5. Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy

    Authors: , , , - Human Gene Therapy Methods 2013 cited by 342

  6. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Betty Muthoni Gikonyo, Dan Gikonyo, Roger J. Hajjar, Kunitoshi Iseki, Hideki Ishii, Greg Knoll, Colin R. Lenihan, Krista L. Lentine, Edgar V. Lerma, Etienne Macedo, Patrick B. Mark, Eisei Noiri, Alberto Palazzuoli, Roberto Pecoits‐Filho, Bertram Pitt, Claudio Rigatto, Patrick Rossignol, Soko Setoguchi, Manish M. Sood, Stefan Störk, Rita S. Suri, Karolina Szummer, Sydney Tang, Navdeep Tangri, Aliza Thompson, Krishnaswami Vijayaraghavan, Michael D. Walsh, Angela Yee‐Moon Wang, Matthew R. Weir - Kidney International 2019 cited by 435

  7. Mitochondrial Morphology, Dynamics, and Function in Human Pressure Overload or Ischemic Heart Disease With Preserved or Reduced Ejection Fraction

    Authors: , , , , , , , , , - Circulation Heart Failure 2019 cited by 145

  8. Extracellular Vesicle–Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2023 cited by 84

  9. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives

    Authors: , , , , , , , , , , , , , , , - European Heart Journal 2017 cited by 414

  10. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID)

    Authors: , , , , , , , , , - Circulation 2011 cited by 749

  11. Modulation of Cardiac Contractility by the Phopholamban/SERCA2a Regulatome

    Authors: , - Circulation Research 2012 cited by 525

  12. Angiogenic Mechanisms of Human CD34 + Stem Cell Exosomes in the Repair of Ischemic Hindlimb

    Authors: , , , , , , , , , - Circulation Research 2017 cited by 308

  13. Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 164

  14. Role of SIRT1 in Modulating Acetylation of the Sarco-Endoplasmic Reticulum Ca 2+ -ATPase in Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , , , , - Circulation Research 2019 cited by 131

  15. Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders

    Authors: , , , , , , , - Journal of Biological Chemistry 2015 cited by 192

  16. Global genome analysis reveals a vast and dynamic anellovirus landscape within the human virome

    Authors: , , , , , , , , , , , , , , - Cell Host & Microbe 2021 cited by 104

  17. Human Cardiac Gene Therapy

    Authors: , , - Circulation Research 2018 cited by 122

  18. Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nicholas R. Banner, Siân E. Harding - Gene Therapy 2020 cited by 93

  19. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial

    Authors: , , , , , , , , , - Journal of Cardiac Failure 2009 cited by 456

  20. SUMO1-dependent modulation of SERCA2a in heart failure

    Authors: , , , , , , , - Nature 2011 cited by 376

  21. Altered Myocardial Calcium Cycling and Energetics in Heart Failure—A Rational Approach for Disease Treatment

    Authors: , , - Cell Metabolism 2015 cited by 214

  22. Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression

    Authors: , , , , , , , , - Molecular Therapy 2015 cited by 111

  23. Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2012 cited by 695

  24. Effect of Intracoronary Administration of AAV1/SERCA2a on Ventricular Remodelling in Patients with Advanced Systolic Heart Failure: Results from the Agent-Hf Randomized Phase 2 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Journal of Heart Failure 2017 cited by 112